Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients

被引：55

作者：

Perinel, Sophie ^{[1
,2
]}

Launay, Manon ^{[3
]}

Botelho-Nevers, Elisabeth ^{[4
]}

Diconne, Eric ^{[1
]}

Louf-Durier, Aurore ^{[1
]}

Lachand, Raphael ^{[1
]}

Murgier, Martin ^{[1
]}

Page, Dominique ^{[1
]}

Vermesch, Regine ^{[1
]}

Thierry, Guillaume ^{[1
]}

Delavenne, Xavier ^{[2
,3
]}

机构：

[1] Ctr Hosp Univ CHU St Etienne, Serv Med Intens & Reanimat, St Etienne, France

[2] Univ Lyon, Inst Natl Sante & Rech Med U1059, Dysfonct Vasculaires & Hemostase, St Etienne, France

[3] CHU St Etienne, Lab Pharmacol Toxicol Gaz Sang, St Etienne, France

[4] CHU St Etienne, Infect Dis Dept, St Etienne, France

来源：

CLINICAL INFECTIOUS DISEASES | 2020年 / 71卷 / 16期

关键词：

hydroxychloroquine; pharmacokinetic; COVID-19; SARS-Cov2; intensive care; PHARMACOKINETICS; TABLETS;

D O I：

10.1093/cid/ciaa394

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Hydroxychloroquine (HCQ) appears to be a promising treatment for COVID-19. However, all ongoing clinical trials with HCQ use different dosing regimens, resulting in various concentrations. Pharmacokinetic studies are therefore needed to define the optimal dosing regimen.

引用

页码：2227 / 2229

页数：3

共 9 条

[1] Steady-state pharmacokinetics of hydroxychloroquine in patients with cutaneous lupus erythematosus [J].

Al-Rawi, H. ;

Meggitt, S. J. ;

Williams, F. M. ;

Wahie, S. .

LUPUS, 2018, 27 (05) :847-852

[2] Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis [J].

Carmichael, SJ ;

Charles, B ;

Tett, SE .

THERAPEUTIC DRUG MONITORING, 2003, 25 (06) :671-681

[3] Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence [J].

Durcan, Laura ;

Clarke, William A. ;

Magder, Laurence S. ;

Petri, Michelle .

JOURNAL OF RHEUMATOLOGY, 2015, 42 (11) :2092-2097

[4] Pharmacokinetics and Bioequivalence Study of Hydroxychloroquine Sulfate Tablets in Chinese Healthy Volunteers by LC–MS/MS [J].

Fan H.-W. ;

Ma Z.-X. ;

Chen J. ;

Yang X.-Y. ;

Cheng J.-L. ;

Li Y.-B. .

Rheumatology and Therapy, 2015, 2 (2) :183-195

[5]

Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI [10.1016/j.ijantimicag.2020.105949, 10.1016/j.ijantimicag.2020.106063]

[6] BIOAVAILABILITY OF HYDROXYCHLOROQUINE TABLETS IN HEALTHY-VOLUNTEERS [J].

TETT, SE ;

CUTLER, DJ ;

DAY, RO ;

BROWN, KF .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 27 (06) :771-779

[7] Pharmacokinetics and Extracorporeal Membrane Oxygenation in Adults: A Literature Review [J].

Tukacs, Monika .

AACN ADVANCED CRITICAL CARE, 2018, 29 (03) :246-258

[8] Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro [J].

Wang, Manli ;

Cao, Ruiyuan ;

Zhang, Leike ;

Yang, Xinglou ;

Liu, Jia ;

Xu, Mingyue ;

Shi, Zhengli ;

Hu, Zhihong ;

Zhong, Wu ;

Xiao, Gengfu .

CELL RESEARCH, 2020, 30 (03) :269-271

[9] In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) [J].

Yao, Xueting ;

Ye, Fei ;

Zhang, Miao ;

Cui, Cheng ;

Huang, Baoying ;

Niu, Peihua ;

Liu, Xu ;

Zhao, Li ;

Dong, Erdan ;

Song, Chunli ;

Zhan, Siyan ;

Lu, Roujian ;

Li, Haiyan ;

Tan, Wenjie ;

Liu, Dongyang .

CLINICAL INFECTIOUS DISEASES, 2020, 71 (15) :732-739

← 1 →